# US 2010/0168002 A1 · Therapeutic peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168002 A1
- Document ID: US20100168002A1
- Status: Published application
- Kind: A1
- Application number: 12/165,149
- Filed: 2008-06-30
- Published: 2010-07-01
- Earliest claimed: 2002-10-02
- Assignees: The University of Bristol
- Inventors: Mumtaz Virji
- Web page: https://patentgrep.com/patent/US20100168002A1

## CPC

- C07K 14/212: {Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a ligand isolated from Moraxella catarrhalis outer membrane protein which binds to CEACAM receptors, said ligand comprising a receptor binding domain comprising an amino acid sequence selected from the group disclosed, or a fragment, homologue, functional equivalent, derivative, degenerate or hydroxylation, sulphonation or glycosylation product or other secondary processing product thereof. The invention also provides medicaments and vaccines comprising said ligand, and their use in the treatment or prophylaxis of infection. Also provided is a screening method for the identification of novel therapeutic compounds.

## Claims

### Claim 1

A ligand which is a part of the whole UspA1 molecule including the CEACAM receptor binding domain, said ligand comprising residues 427 to 623 of SEQ ID NO: 2 or a fragment thereof required for CEACAM receptor binding.

### Claim 2 (depends on 1)

The ligand according to claim 1, wherein the ligand consists of an amino acid sequence selected from the group consisting of residues 463 to 863, 527 to 623, 527 to 668, 527 to 863, 427 to 623, 427 to 668 and 427 to 863 of SEQ ID NO: 2.

### Claim 3 (depends on 1)

A medicament comprising the ligand according to claim 1 and one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers, or preservatives.

### Claim 4 (depends on 1)

A method for the treatment or prevention of infection in an individual in need thereof comprising administering an effective amount of a ligand according to claim 1.

### Claim 5 (depends on 1)

A method for the treatment or prevention of a disease in an individual in need thereof, in which CEACAM receptors are involved in the cellular targeting of the pathogen which causes the disease, comprising administering an effective amount of a ligand according to claim 1.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the disease is selected from the group consisting of infection, respiratory disease, neoplastic diseases and associated conditions of neoplastic diseases, and angiogenesis.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the infection is of, or has occurred via, a mucosal membrane.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the infection is caused by Neisseria meningitidis, Haemophilus influenzae or Moraxella catarrhalis.

### Claim 9 (depends on 1)

A method for the prophylaxis or treatment of otitis media in an individual in need thereof comprising administering an effective amount of a ligand according to claim 1.

### Claim 10 (depends on 1)

A method for the identification of blocking reagents for use as therapeutic agents comprising screening potential therapeutic agents for their ability to mimic, or for their homology to, the ligand according to claim 1.

### Claim 11 (depends on 1)

A vaccine comprising the ligand according to claim 1 and one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers, or preservatives.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 5)

The method according to claim 5, wherein the ligand consists of an amino acid sequence selected from the group consisting of residues 463 to 863, 527 to 623, 527 to 668, 527 to 863, 427 to 623, 427 to 668 and 427 to 863 of SEQ ID NO: 2 or a fragment or functional equivalent thereof which retains CEACAM binding ability.

### Claim 16 (depends on 15)

The method according to claim 15 wherein the disease is selected from the group consisting of infection, respiratory disease, neoplastic disease and associated conditions of neoplastic disease, and angiogenesis.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the pathogen infects, or enters via, a mucosal membrane.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the pathogen infects, or enters via, a mucosal membrane.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the pathogen which causes the disease is selected from the group consisting of Neisseria meningitidis, Haemophilus influenzae and Moraxella catarrhalis.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the disease is otitis media.

### Claim 21 (depends on 3)

The medicament according to claim 3, wherein the ligand consists of an amino acid sequence selected from the group consisting of residues 463 to 863, 527 to 623, 527 to 668, 527 to 863, 427 to 623, 427 to 668 and 427 to 863 of SEQ ID NO: 2.

### Claim 22 (depends on 4)

The method according to claim 4, wherein the ligand consists of an amino acid sequence selected from the group consisting of residues 463 to 863, 527 to 623, 527 to 668, 527 to 863, 427 to 623, 427 to 668 and 427 to 863 of SEQ ID NO: 2.
